

CERTIFICATION:

American Board of Pediatrics (#24095)	1980
American Board of Pediatrics (Hematology/Oncology, #568)	1982

LICENSURE:

State of California, #G034542	DEA# AA7785922
-------------------------------	----------------

HONORS AND AWARDS:

Francis Wayland Scholar, Brown University	1969
Society of Sigma Xi, Brown University	1972
Phi Beta Kappa, Brown University	1972
Henry J. Kaiser Award for Excellence in Teaching of Clinical Medicine Stanford University School of Medicine	1984, 1990
Profiled in "I want to grow hair, I want to grow up, I want to go to Boise" (Chapter 5) by Erma Bombeck, Harper Row, NY 1989	1989
"For Those Who Care" Award, KRON TV, San Francisco, CA	1990
"Golden Sword" Award, American Cancer Society, California Division	1991
Henry J. Kaiser Award for Excellence in Teaching of Preclinical Medicine Stanford University School of Medicine	1992, 1998
Letter of Commendation from the Committee on Courses and Curriculum for Excellence in Teaching: Med/Peds 205, Hematology Stanford University School of Medicine	1992, 93, 94, 95, 96, 97, 98, 99, 2000, 01, 02
"Ronnie" Award for service, Ronald McDonald House, Palo Alto, CA	1993
Named "Master Advisor" for academic advising at Stanford University	1995
The Koshland Prize, Peninsula Community Foundation	1995
Alwin C. Rambar-James B.D. Mark Award for Excellence in Patient Care Stanford University School of Medicine	2002
"Golden Coffee Cup" award for exceptional commitment to resident education Lucile Packard Children's Hospital at Stanford	2003
AcademicKeys "Who's Who in Medical Sciences Education"	2005
"Lifesaver" Award for individual commitment to treating and curing cancer Joanne Pang Foundation	2011

RELATED PROFESSIONAL ACTIVITIES:A. Pediatric Oncology Group (POG) and Children's Oncology Group (COG):

- National Coordinator, front-line studies for treatment of advanced lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia
- Member of New Acute Lymphoblastic Leukemia Committee (POG), 1985-2000
- Member of Non-Hodgkin's Lymphoma Core Committee (POG), 1986-1994
- Member of Bone Marrow Transplant Core Committee (POG), 1991-2000
- Chairman, T-cell Disease Core Committee (POG), 1992-1999
- Member of Nominating Committee (POG), 1989-90
- Member of Executive Committee (POG), 1991-1994
- Member, ALL protocol development committee (POG/CCG Fusion), 1999-2000
- Member, BMT transition committee (POG/CCG Fusion), 1999-2000
- Member, Hematopoietic Stem Cell Transplant Discipline Committee(COG), 2000-2003
- Member, New ALL protocol development committee(COG), 2000-2003

B. Stanford University Medical Center:School of Medicine:

- Section Leader/Lecturer, Pre-clinical Hematology Course (Ped/Med 205) 1991-2003
- Course Director, Impact of Childhood Chronic Illness (Ped 281) 1993-2002
- Committee of Five, Medical School Faculty Council Senate, 1992-93
- Departmental Senator, Senate of the Medical School Faculty Council, 1991-1997

- Committee on the well being of medical students, 1985-1992 (Co-chair, 1988-90)
- Medical School Convocation Committee, 1992-96

Stanford University Hospital:

- Bone Marrow Transplant Review Committee, 1987-2003

Lucile Salter Packard Children's Hospital at Stanford:

- Blood and Transfusion Committee, Chairman, 1984-92
- Infection Control Committee, 1986-2003
- Pharmacy and Therapeutics Committee 1985-2003; Chairman 1992-2001
- Nutrition and TPN Committee, 1987-91
- Medical Advisor, Child Life Group, 1985-1993
- Home Health Care Committee, 1993-1997
- Peer Review Committee, 1997-1999

C. Stanford University:

- Academic Advisor to undergraduate students in the Natural Sciences, 1989-1999
- Member, Administrative Panel on Human Subjects in Medical Research (Panel 3), 1995-1999
- Chair, Administrative Panel on Human Subjects in Medical Research (Panel 4), 1999-2003
- Chair, Administrative Panel on Human Subjects in Medical Research (Panel 7), 2005-present
- Vice Chair, Administrative Panel on Human Subjects in Medical Research and Stem Cell Research Oversight Committee (Panel 3), 2009-present

D. Community:

- Chairman of the Children and Cancer Task Force, American Cancer Society, (California Division), 1991-93; Member, 1989-93
- Member, Patient Services Committee, American Cancer Society, (California Division), 1991-93.
- Member, Celebration of Life Task Force, American Cancer Society, (California Division), 1991-92
- Member, Courageous Kids Committee, American Cancer Society (Santa Clara Unit), 1990-2020
- Founding Member and Director, Touchstone Support Network, 1980-98 (A peer support group for children with life-threatening illnesses and their families)
- Director, Okizu Foundation (formerly RJ Sturhahn Fnd), 1985-2020 (A non-profit foundation for the benefit of children with cancer and their families)
- Volunteer, Camp Okizu: Emeritus Medical Director, cabin counselor, Unit Leader, Junior Staff Director, Archery Instructor, Staff training leader, etc., 1982-present
- Facilitator, "Kids Helping Kids" support group for children of adult cancer patients, Cancer Support and Education Center, Menlo Park, CA, 1994-96
- Member, American Cancer Society (California Division) Youth Advocacy Strategic Agenda Group (Youth Initiative Summit), 1997-1998
- Director, Parents Helping Parents (The Family Resource Center), 1998-2004 (A non-profit resource center for parents of special needs children)
- Volunteer and Advisor, Camp Kesem Stanford. Served on Steering Committee, Advisory Committee, and as a trainer at the annual counselor training retreat, 2001-2024
- Member, Peer Review Committee on Psychosocial, Behavioral and Policy Research, American Cancer Society, 2003-2006
- Children's Oncology Camping Association International, Board of Directors 2003-2019, 2023-present; Chair, Research and Education Committee 2007-2014, President-Elect, 2014-16; President, 2016-18; Immediate Past President, 2018-19; Chair, Gold Ribbon Accreditation Committee 2023-present.
- Member, Sibling Partnership for Advocacy, Research, and Care in Childhood Cancer, 2014-present.
- Founding Member, Board of Directors, Camp Kaleidoscope (a program dedicated to supporting the well-being of children with a parent who has or had cancer), 2024 - present

Book Chapters:

1. **Amylon MD.** The role of parenteral nutritional support in pediatric oncology. In: J Kerner (ed) Pediatric Parenteral Nutrition, p 323-7. John Wiley and Sons. New York, 1983.
2. **Amylon MD**, Link MP and Murphy SB. Malignant T-cell and other non-Hodgkin's lymphoma. In: A Barrett and PA Voute (eds) Cancer in Children, Second Edition, p 152-63. Springer-Verlag, London, 1986.
3. Glader BE and **Amylon MD.** Erythropoiesis and evaluation of the child with anemia. In VC Kelley (ed) Practice of Pediatrics, Vol. 5, Chapter 41, p 1-16, Harper and Row, Philadelphia, 1987.
4. Chao NJ, **Amylon MD**, Long GD, Negrin RS, Hoppe RT, Horning SJ and Blume KG. Bone marrow transplantation for hematologic malignancies: The Stanford experience. In: P Terasaki (ed) Clinical Transplants 1990, p 157-63. Los Angeles, 1990.
5. **Amylon, MD.** Treatment of T-lineage acute lymphoblastic leukemia. In: Childhood Acute Lymphoblastic Leukemia--Part II. Pochedly and Civin (eds) Hematology/Oncology Clinics of North America 4(5):937-949, 1990.
6. Glader BE and **Amylon MD.** Hemostatic Disorders in the Newborn. In Taeusch HW, Ballard RA and Avery ME (eds) Diseases of the Newborn, sixth edition (chapter 84), p 777-790, W. B. Saunders, 1991.
7. Blume KG and **Amylon MD.** The evaluation and counseling of the BMT candidate. In: Bone Marrow Transplantation, Forman SJ, Blume KG and Thomas ED eds, Second edition (Chapter 33), p 371-380, Blackwell Scientific Publications, 1999.
8. Blume KG and **Amylon MD.** The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation. In: Thomas' Hematopoietic Cell Transplantation, Blume KG, Forman SJ and Appelbaum FR eds, Third Edition (Chapter 33), p 449-462, Blackwell Scientific Publications, 2004.

Original Publications:

1. Paryani SB, Donaldson SS, **Amylon MD**, and Link MP. Cranial nerve involvement in children with leukemia and lymphoma. J Clin Oncol 1(9):542-545, 1983.
2. Link M, Warnke R, Finlay J, **Amylon M**, Miller R, Dilley J, and Levy R. A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies. Blood 62(4):722-728, 1983.
3. Paryani SG, Arvin AM, Koropchak CM, Wittek AE, **Amylon MD**, Dobkin MB and Budinger MD. Varicella zoster antibody titers after the administration of intravenous immune serum globulin or varicella zoster immune globulin. Am J Med 76(3A):124-127, 1984.
4. Paryani SG, Arvin AM, Koropchak CM, Dobkin MB, Wittek AE, **Amylon MD** and Budinger MD. Comparison of varicella zoster antibody titers in patients given intravenous immune serum globulin or varicella zoster immune globulin. J Pediatr 105(2):200-205, 1984.
5. **Amylon MD**, Link MP and Glader BE. Immune thrombocytopenia associated with acute nonlymphocytic leukemia. J Pediatr 105(5):776-778, 1984.

6. Rivera GK, Buchanan G, Boyett JM, Camitta B, Ochs J, Kalwinsky D, **Amylon M**, Vietti TJ and Crist WM. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study. *N Engl J Med* 315(5):273-278, 1986.
7. Smith SD, Link MP, Trela M, **Amylon M**, Sklar J, Morgan R and Hecht F. Chromosome 9 abnormalities in childhood T-cell leukemia [letter]. *N Engl J Med* 315(3):195-196, 1986.
8. **Amylon MD**, Perrine SP and Glader BE. Prednisone stimulation of erythropoiesis in leukemic children during remission. *Am J Hematol* 23(2):179-181, 1986.
9. Smith SD, Morgan R, Galili N, **Amylon MD**, Link MP, Hecht F, Sklar J and Glader BE. Establishment and characterization of a common acute lymphoblastic leukemia cell line with a deletion of chromosome 3 band q26. *Cancer Res* 47(6):1652-1656, 1987.
10. Smith SD, Morgan R, Gemmell R, **Amylon MD**, Link MP, Linker C, Hecht BK, Warnke R, Glader BE and Hecht F. Clinical and biological characterization of T-cell neoplasias with rearrangements of chromosome 7 band q34. *Blood* 71(2):395-402, 1988.
11. Carroll WL, Link MP, Cleary ML, Bologna S, Carswell C, **Amylon MD**, Smith SD and Levy R. Idiotype as a tumor specific marker in childhood B-cell acute lymphoblastic leukemia. *Blood* 71(4):1068-1073, 1988.
12. Fritz GK, Williams JA and **Amylon M**. After treatment ends: psychosocial sequelae in pediatric oncology survivors. *Am J Orthopsychiatry* 58(4):552-561, 1988.
13. Blume KG, Schmidt GM, Chao NJ, Krance RA, **Amylon MD** and Forman SJ. Bone marrow transplantation from histocompatible sibling donors for patients with acute lymphoblastic leukemia. *Bone Marrow Transplantation* 4(Suppl.2):18, 1989.
14. Rogers ZA, Bergstrom SK, **Amylon MD**, Buchanan GR and Glader BE. Reduced neutrophil counts in children with transient erythroblastopenia of childhood. *J Pediatr* 115(5):746-748, 1989.
15. Blume KG, Schmidt GM, Chao NJ, Konrad PN, **Amylon MD** and Forman SJ. Bone marrow transplantation for acute lymphoblastic leukemia. In: Gale RP, Hoelzer D (ed). *Acute Lymphoblastic Leukemia: Proceedings of a Wyeth-Ayerst-UCLA Western Workshop*. Tapatio Springs, Texas 1990. New York. Wiley-Liss, pp 279-283.
16. Stevens SK, Moore SG, and **Amylon MD**. Repopulation of marrow after transplantation: MR imaging with pathologic correlation. *Radiology* 175(1):213-218, 1990.
17. Carroll AJ, Crist WM, Link MP, **Amylon, MD**, Pullen DJ, Ragab AH, Buchanan GR, Wimmer RS and Vietti TJ. The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Blood* 76(6):1220-1224, 1990.
18. Edelstein J, **Amylon M**, and Walsh JA. Dermatoglyphics and acute lymphocytic leukemia in children. *J Pediatr Oncol Nurs* 8(1):30-38, 1991.
19. Diaz P, Au D, Smith S, **Amylon M**, Link M, Smith S and Arvin A. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. *Pediatrics* 87(2):166-170, 1991.

20. Russo C, Carroll A, Kohler S, Borowitz M, **Amylon M**, Homans A, Kedar A, Shuster J, Land V, Crist W, Pullen J and Link M. Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. *Blood* 77(5):1050-1056, 1991.
21. Forman SJ, Schmidt GM, Nademanee AP, **Amylon MD**, Chao NJ, Fahey JL, Konrad PN, Margolin KA, Niland JC, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Somlo G, Stein AS, and Blume KG. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. *J Clin Oncol* 9(9):1570-1574, 1991.
22. Chao NJ, Forman SJ, Schmidt GM, Snyder DS, **Amylon MD**, Konrad PN, Nademanee AP, O'Donnell MR, Parker PM, Stein AS, Smith E, Wong RM, Hoppe RT and Blume KG. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. *Blood* 78(8):1923-1927, 1991.
23. Watson MS, Land VJ, Carroll AJ, Pullen J, Borowitz MJ, Link M, **Amylon M** and Behm FG. t(2;14)(p13;q32): A recurring abnormality in lymphocytic leukemia. A Pediatric Oncology Group Study. *Cancer Genet Cytogenet* 58(2):121-124, 1992.
24. Vietti TJ, Shuster JJ, **Amylon M**, Berard C, Borowitz M, Bowman WP, Brecher M, Castleberry R, Frankel L, Goorin A, Hayes FA, Hvizdala E, Krischer JP, Land V, Link M, McWilliams N, Murphy S, Pick T, Pullen J, Ravindranath Y, Smith EI, Steuber CP, Sullivan M, van Eys J, Wharam M, Crist W. Progress against childhood cancer: The Pediatric Oncology Group Experience. *Pediatr* 89(4):597-600, 1992.
25. Crist W, Shuster J, Look T, Borowitz M, Behm F, Bowman P, Frankel L, Pullen J, Krance R, Steuber P, Camitta B, **Amylon M**, Link M and Land V. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. *Leukemia* 6 (Suppl 2):162-167, 1992.
26. Chao NJ, Stein AS, Long GD, Negrin RS, **Amylon MD**, Wong RM, Forman SJ and Blume KG. Busulfan/Etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. *Blood* 81(2):319-323, 1993.
27. Bash RO, Crist WM, Shuster JJ, Link MP, **Amylon M**, Pullen J, Carroll AJ, Buchanan GR, Smith RG and Baer R. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to the TAL1 locus: a Pediatric Oncology Group study. *Blood* 81(8):2110-2117, 1993.
28. Carmack MA, Twiss J, Enzmann DR, **Amylon MD** and Arvin AM. Multifocal leukoencephalitis caused by varicella-zoster virus in a child with leukemia: successful treatment with acyclovir. *Pediatr Infect Dis J* 12(5):402-406, 1993.
29. Mogul M, Hartman G, Donaldson S, Gelb A, Link M, **Amylon M**, Glader B. Langerhans' cell histiocytosis presenting with the superior vena cava syndrome: A case report. *Med Pediatr Oncol* 21(6):456-459, 1993.
30. Chao NJ, Schmidt GM, Niland JC, **Amylon MD**, Dagens AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG and Forman SJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. *N Engl J Med* 329(17):1225-1230, 1993.
31. Hunger SP, Tkachuk DC, **Amylon MD**, Link MP, Carroll AJ, Welborn JL, Willman CL and Cleary ML. HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. *Blood* 81(12):3197-3203, 1993.

32. Snyder DS, Chao NJ, **Amylon MD**, Taguchi J, Long GD, Negrin RS, Nademanee AP, O'Donnell MR, Schmidt GM, Stein AS, Parker PM, Smith EP, Stepan DE, Molina A, Lipsett JA, Hoppe RT, Niland JC, Dagens AC, Wong RM, Forman SJ and Blume KG. Fractionated total body irradiation and high-dose Etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. *Blood* 82(9):2920-2928, 1993.
33. Walters M, Sullivan KM, O'Reilly RJ, Bolad F, Blume K, **Amylon M**, Johnson L, Klemperer M, Graham-Pole J, Appelbaum FR, Bernstein I, Hansen JA, Sanders JE, Storb R and Thomas ED. Bone marrow transplantation for thalassemia: the United States experience [Published erratum appears in *Am J Pediatr Hematol Oncol* 1994 May;16(2):189]. *Am J Pediatr Hematol Oncol* 16(1):11-17, 1994.
34. Snyder DS, Negrin RS, O'Donnell MR, Chao NJ, **Amylon MD**, Long GD, Nademanee AP, Stein AS, Parker PM, Smith EP, Somlo G, Margolin K, Molina A, Stepan DE, Lipsett JA, Hoppe RT, Slovak ML, Niland JC, Dagens AC, Wong RM, Forman SJ and Blume KG. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. *Blood*, 84(5):1672-1679, 1994.
35. Blume KG, Long GD, Negrin RS, Chao NJ, Kusnierz-Glaz C and **Amylon MD**. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. *Bone Marrow Transplant* 14(Suppl 4):S9-10, 1994.
36. Bash RO, Hall S, Timmons CF, Crist WM, **Amylon M**, Smith RG and Baer R. Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A Pediatric Oncology Group study. *Blood*, 86(2):666-676, 1995.
37. O'Donnell MR, Long GD, Parker PM, Niland J, Nademanee A, **Amylon M**, Chao N, Negrin RS, Schmidt GM, Slovak ML, Smith EP, Snyder DS, Stein AS, Traweek T, Blume KG and Forman SJ. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. *J Clin Oncol* 13(12):2973-2979, 1995.
38. Priest JR, Watterson J, Strong L, Huff V, Woods WG, Byrd RL, Friend SH, Newsham I, **Amylon MD**, Pappo A, Mahoney DH, Langston C, Heyn R, Kohut G, Freyer DR, Bostrom B, Richardson MS, Barredo J and Dehner LP. Pleuropulmonary blastoma: a marker for familial disease. *J Pediatr* 128(2):220-224, 1996.
39. Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, **Amylon MD**, Brown BW, Wong RM and Blume KG. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. *Biol Blood Marrow Transplant* 2(2):76-85, 1996.
40. Randle CJ, Frankel LR and **Amylon MD**. Early predictors of mortality in pediatric patients with acute leukemia and pneumonia. *Chest* 109(2):457-461, 1996.
41. Kusnierz-Glaz CR, Schlegel PG, Wong RM, Schriber JR, Chao NJ, **Amylon MD**, Hu WW, Negrin RS, Lee Y, Blume KG, Long GD. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. *J Clin Oncol* 15(1):18-25, 1997.
42. **Amylon MD**, Co JT, Snyder DS, Donaldson SS, Blume KG and Forman SJ. Fractionated total body irradiation with high dose etoposide for allogeneic bone marrow transplant in pediatric patients with high risk hematologic malignancies early in the course of their disease. *J Pediatr Hematol Oncol* 19(1):54-61, 1997.

43. Matherly LH, Taub JW, Wong SC, Simpson PM, Ekizian R, Buck S, Williamson M, **Amylon M**, Pullen J, Camitta B, Ravindranath Y. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. *Blood* 90(2):578-589, 1997.
44. Diccianni MB, Batova A, Yu J, Vu T, Pullen J, **Amylon M**, Pollock BH, Yu AL. Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. *Leukemia Research* 21(6):549-558, 1997.
45. Long GD, **Amylon MD**, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, and Blume KG. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. *Biol Blood Marrow Transplant* 3(6):324-330, 1997.
46. Laver J, **Amylon M**, Desai S, Link M, Schwenn M, Mahmoud H, Shuster J. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group study. *J Clin Oncol* 16(2):522-526, 1998.
47. Look KA and **Amylon MD**. Therapy of acute lymphoblastic leukemia of T-cell phenotype. *International Journal of Pediatric Hematology/Oncology* 5(2-4):73-80, 1998.
48. Lee YS, Kristovich KM, Ducore JM, Vichinsky E, Crouse VL, Glader BE and **Amylon MD**. Bone marrow transplant in thalassemia. A role for radiation? *Ann NY Acad Sci* 850:503-505, 1998.
49. **Amylon MD**, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, and Murphy SB. Intensive high dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group Study. *Leukemia*, 13(3):335-342, 1999.
50. Batova A, Diccianni MB, Omura-Minamisawa M, Yu J, Carrera CJ, Bridgeman LJ, Kung FH, Pullen J, **Amylon MD** and Yu AL. Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. *Cancer Res* 59(7):1492-1497, 1999.
51. Ross M, Schmidt GM, Niland JC, **Amylon MD**, Dagens AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Forman SJ, Blume KG, and Chao NJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. *Biol Blood Marrow Transplant* 5(5):285-291, 1999.
52. Abdel-Mageed A, Graham-Pole J, Del Rosario ML, Longmate J, Ochoa S, **Amylon M**, Eifenbein GL, Janiec J, Jansen J, and Lazarus HM. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplantation. *Bone Marrow Transplant*, 23(9):929-932, 1999.
53. Pullen J, Shuster JJ, Link M, Borowitz M, **Amylon M**, Carroll AJ, Land V, Look AT, McIntyre B, and Camitta B. Significance of commonly used prognostic factors differs for children with T-cell acute lymphocytic leukemia (ALL) as compared to those with B-precursor ALL: A Pediatric Oncology Group (POG) study. *Leukemia*, 13(11):1696-1707, 1999.

54. Snyder DS, Nademanee AP, O'Donnell MR, Parker PM, Stein AS, Margolin K, Somlo G, Molina A, Spielberger R, Kashyap A, Fung H, Slovak ML, Dagens A, Negrin RS, **Amylon MD**, Blume KG, and Forman SJ. Long-term follow-up of twenty-three patients with Philadelphia-chromosome positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. *Leukemia* 13(12):2053-2058, 1999.
55. Challinor JM, Miaskowski CA, Franck LS, Slaughter RE, Matthay KK, Kramer RF, Veatch JJ, Paul SM, **Amylon MD**, Moore IM. Somatization, anxiety and depression as measures of health-related quality of life of children/adolescents with cancer. *Int J Cancer Suppl* 83(S12): 52-57, 1999.
56. Bennett CL, Stinson TJ, Lane D, **Amylon M**, Land VJ, and Laver JH. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: A case for prospective economic analysis in cooperative group trials. *Med Pediatr Oncol* 34(2):92-96, 2000.
57. Woo MH, Shuster JJ, Chen C, Bash RO, Behm FG, Camitta B, Felix CA, Kamen BA, Pui CH, Raimondi SC, Winick NJ, **Amylon MD** and Relling MV. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. *Leukemia* 14(2):232-237, 2000.
58. Laver JH, Barredo JC, **Amylon M**, Schwenn M, Kurtzberg J, Camitta BM, Pullen J, Link MP, Borowitz M, Ravindranath Y, Murphy SB, Shuster J. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report. *Leukemia* 14(3):369-373, 2000.
59. Griffin TC, Shuster JJ, Buchanan GR, Murphy SB, Camitta BM, and **Amylon MD**. Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. *Leukemia*, 14(5):792-795, 2000.
60. Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston LJ, **Amylon MD**, Tierney DK, O'Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung H, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Blume KG. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. *Biol Blood Marrow Transplant* 6(3):254-261, 2000.
61. Schneider NR, Carroll AJ, Shuster JJ, Pullen DJ, Link MP, Borowitz MJ, Camitta BM, Katz JA and **Amylon MD**. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group report of 343 cases. *Blood*.96(7):2543-2549, 2000.
62. Palmer L., Erickson S., Shaffer T., Koopman C., **Amylon M.**, & Steiner H. Themes arising in group therapy for adolescents with cancer and their parents. *International Journal of Rehabilitation and Health*, 51 (1), 43-54, 2000.
63. Frankovich JR, Donaldson SS, Lee Y, Wong RM, **Amylon M**, and Verneris MR. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes. *Biol Blood Marrow Transplant* 7(1):49-57 2001.
64. Deeg HJ, **Amylon MD**, Harris RE, Collins R, Beatty PG, Feig S, Ramsay N, Territo M, Khan SP, Pamphilon D, Leis JF, Burdach S, Anasetti C, Hackman R, Storer B, Mueller B. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. *Biol Blood Marrow Transplant* 7(4):208-215, 2001.

65. Shah SJ, Taub JW, Witt TL, Pollock BH, Ding BC, Moore DS, **Amylon M**, Pullen J, Ravindranath Y, Matherly LH. Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia. *Br J Haematol*. 113(3):746-56, 2001.
66. Winter SS, Sweatman J, Shuster JJ, Link MP, **Amylon MD**, Pullen J, Camitta BM, and Larson RS. Bone marrow stroma-supported culture of T-lineage acute lymphoblastic leukemic cells predicts treatment outcome in children: a Pediatric Oncology Group study. *Leukemia* 16(6):1121-1126, 2002.
67. Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, **Amylon MD**, Bash RO, Behm FG, Camitta, BM, Pui, C-H, Raimondi SC, and Relling MV. Genetic Polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. *Pharmacogenetics* 12(8):605-611, 2002.
68. Challinor J, Moore IK, Kramer R, Pasvogel A, Leung K, **Amylon M**, Hutter J, and Matthay K. Development and testing of the School Competency Assessment Scale. *J Pediatr Oncol Nurs* 20(2):56-64, 2003.
69. Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A, **Amylon M**, Sullivan KM, Storb RF, and Walters MC. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta thalassemia. *Biol Blood Marrow Transplant* 8(8):519-528, 2003.
70. Jamieson CH, **Amylon MD**, Wong RM and Blume KG. Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience. *Exp Hematol* 31(10):981-986, 2003.
71. Packman W, Fine J, Chesterman B, vanZutphen K, Golan R and **Amylon MD**. Camp Okizu: Preliminary Investigation of a Psychological Intervention for Siblings of Pediatric Cancer Patients. *Children's Health Care* 33(3): 201-215, 2004.
72. Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, **Amylon MD**, Link MP, and Agarwal R. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: Results and prognostic indices. *J Clin Oncol* 22(22):4532-4540, 2004.
73. Packman W, Greenhalgh J, Chesterman B, Shaffer T, Fine J, vanZutphen K, Golan R and **Amylon MD**. Siblings of pediatric cancer patients: the quantitative and qualitative nature of quality of life. *J Psychosocial Oncol* 23(1):87-108, 2005.
74. Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM and **Amylon MD**. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. *Pediatr Blood Cancer*, 46(2):179-186, 2006.
75. Sandler ES, Homans A, Mandell L, **Amylon M**, Wall DA, Devidas M, Buchanan GR, Lipton JM and Billett AL. Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a Pediatric Oncology Group pilot feasibility study. *J Pediatr Hematol Oncol*, 28(4):210-215, 2006.
76. Packman W, Mazaheri M, Sporri L, Long JK, Chesterman B, Fine J, **Amylon MD**. Projective drawings as measures of psychosocial functioning in siblings of pediatric cancer patients from the Camp Okizu study. *J Pediatr Oncol Nurs*, 25(1):44-55, 2008.
77. Dvorak CC, Wright NB, Wong WB, Kristovich KM, Matthews EW, Weinberg KI, **Amylon MD**, Agarwal R. Safety of hematopoietic stem cell transplantation in children less than three years of age. *Pediatr Hematol Oncol*, 25(8):705-22, 2008.

78. Wu, Y. P., Prout, K., Roberts, M. C., Parikshak, S., and **Amylon, M. D.** Assessing experiences of children attending a camp for children with cancer and their siblings: A preliminary study. *Child and Youth Care Forum*, 40, 121-133, 2011.
79. Wu, Y.P., Geldhof, G.J., Roberts, M.C., Parikshak, S., and **Amylon, M.D.** Initial Examination of a New Questionnaire Assessing Perceived Social Support in Summer Camp and Home Environments for Children with Cancer and their Siblings. *Children's Health Care*, 42(1), 67-84, 2014.
80. Martiniuk AL, **Amylon MD**, Briery BG, Shea-Perry M, Kelsey KP, Lam GW, Körver S. Camper learning and friendship at pediatric oncology camps in North America. *J Psychosoc Oncol.*;32(2):234-44. doi: 10.1080/07347332.2013.874001, 2014
81. Martiniuk A, Silva M, **Amylon M**, Barr R. Camp programs for children with cancer and their families: Review of research progress over the past decade. *Pediatr Blood Cancer.* May;61(5):778-87, 2014. doi: 10.1002/pbc.24912. Epub 2014 Jan 7.
82. Wallace, Jo; Packman, Wendy; Huffman, Lynn C.; Horn, Biljana; Cowan, Morton; **Amylon, Michael D.**; Kahn, Coleen; Cordova, Matt & Moses, Jim. Psychosocial Changes Associated with Participation in Art Therapy Interventions for Siblings of Pediatric Hematopoietic Stem Cell Transplant Patients. *Art Therapy: Journal of the American Art Therapy Association*, 31(1), 4-11, 2014
83. Wu, Yelena P., Hung, Man, Franklin, Jeremy D., Samhouri, Mahasen, Simons, Laura and **Amylon, Michael D.** Validation of a measure of children's perceptions of their oncology camp experience: a national study. *Psycho-Oncology*,25(1), 112-114, 2016. Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/pon.3792, 2015.
84. Canter, K.S., Wu, Y.P., Odar, C., Parikshak, S., Roberts, M.C., and **Amylon, M.D.** The relationship between attitudes toward illness and quality of life for children with cancer and healthy siblings. *Journal of Child & Family Studies*. 24(9), 2693-2698, 2015. DOI 10.1007/s10826-014-0071-9
85. Wu, Yelena P.; McPhail, Jessica; Mooney, Ryan; Martiniuk, Alexandra; and **Amylon, Michael D.** A Multi-Site Evaluation of Summer Camps for Children with Cancer and their Siblings. *Journal of Psychosocial Oncology*,34:6, 449-459, 2016. DOI: [10.1080/07347332.2016.1217963](https://doi.org/10.1080/07347332.2016.1217963) ISSN: 0734-7332.
86. Gregory, D., Van Puymbroeck, M., Crowe, B., Garst, B., & **Amylon, M.** (September 21, 2021). The influence of a peer support camp on mitigating emotional distress in siblings of children with cancer. *Journal of Pediatric Oncology Nursing*. 39(2) DOI: <https://doi.org/10.1177/10434542211041929>
87. Gregory, D., Van Puymbroeck, M., Crowe, B.M., Garst, B., & **Amylon, M.** (2022). The lived experience of siblings of children with cancer who attended a peer support camp in the United States. *Qualitative Health Research*. <https://doi.org/10.1177/10497323221095478>
88. McEvoy, MT; Cowfer, BA; Knutson, L; and **Amylon, MD.** (August 14, 2024) The Case for Specialty Summer Camp: A Palliative Care Perspective. *Pediatrics* (2024) 154 (3): e2023063183. <https://doi.org/10.1542/peds.2023-063183>

89. Gregory, D., Van Puymbroeck, Crower, B., Garst, B., & **Amylon, M.** (2025). The influence of a peer support camp on fostering resilience, posttraumatic growth, and quality of life in siblings of children with cancer. *Journal of Park and Recreation Administration*. doi:10.18666/JPRA-2025-12833
- 90.

Abstracts and Presentations:

1. MacKintosh FR, Louie AC, Evans TL, **Amylon MD** and Sikic BI. Clonal heterogeneity in a human ovarian adenocarcinoma. Proc Am Soc Clin Oncol 22:379, 1981.
2. Glader BE, Link MP, **Amylon MD** and Backer K. Adenosine deaminase (ADA) activity in bone marrow mononuclear cells: A marker of minimal disease in T-cell leukemia/lymphoma. Ped Res 16:205A, 1982.
3. Paryani SB, Donaldson SS, **Amylon MD** and Link MP. Cranial nerve involvement in children with leukemia and lymphoma. Radiat-Oncol-Biol-Phy 8(104), 1982.
4. Glader BE, Link MP, **Amylon MD**, Perrine SP and Backer K. Heterogeneity of acute lymphoblastic leukemia (ALL) as revealed by adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) activity. Blood 60(5, Suppl 1):126A, 1982.
5. **Amylon MD**, Link MP and Blader BE. Immune thrombocytopenia associated with acute non-lymphocytic leukemia (ANLL). Clin Res 31:115A, 1983.
6. **Amylon MD**, Perrine SP and Glader BE: Prednisone-induced stimulation of erythropoiesis in acute lymphoblastic leukemia (ALL): Evidence for increased BFU-E and CFU-E formation. Blood 62:164A, 1983.
7. Glader BE, Link MP, **Amylon MD** and Backer K. Adenosine deaminase (ADA) activity in bone marrow (BM) mononuclear cells: A sensitive biochemical marker of minimal disease in patients with T-cell leukemia/lymphoma. Blood 62:172A, 1983.
8. Carroll WL, **Amylon MD**, Link MP, Backer K and Glader BE: Childhood monosomy 7 syndrome: A familial disorder? Ped Res 18:237A, 1984.
9. **Amylon M**, Murphy S and Pullen J. Treatment of lymphoid malignancies according to immune phenotype: preliminary results in T-cell disease. Proc Am Soc Clin Oncol 7:#871, 1988.
10. Rogers ZR, Bergstrom SK, **Amylon MD**, Buchanan GR and Glader BE. Reduced neutrophil counts in patients with transient erythroblastopenia of childhood. Ped Res 23(4, part 2):346A, 1988.
11. Carroll AJ, Link MP, **Amylon MD**, Pullen DJ and Crist WM. A new nonrandom 8;14 translocation in children with acute lymphoblastic leukemia. Am J Human Genetics 43(Suppl 3):A21, 1988.
12. Russo CL, Carroll A, **Amylon M**, Lange W, Sklar J and Link MP. The Philadelphia chromosome and monosomy 7 in childhood acute leukemia. Am J Human Genetics 43(Suppl 3):A32, 1988.
13. Tycko B, Palmer JD, Smith SD, **Amylon M**, Link M and Sklar J. Polymerase chain reaction (PCR) amplification of rearranged gamma T-cell receptor genes using junction specific oligonucleotides: application to detection of minimal residual disease in acute lymphocytic leukemia. Lab Inves 60(1):99A, 1989.
14. Carroll AJ, Link MP, **Amylon MD**, Pullen DJ, and Crist WM. A new translocation, t(1;14)(p34;q11), in T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Am J Human Genetics 45(Suppl 4):A17, 1989.

15. Russo C, Carroll A, Borowitz M, Kohler S, Shannon K, Forman E, Cook B, **Amylon M**, Pullen J and Link M. The Philadelphia chromosome with monosomy 7 in childhood acute lymphoblastic leukemia. Proc Am Soc Clin Oncol 8:825A, 1989.
16. Land VJ, Pullen DJ, Shuster JJ, Alvarado C, **Amylon M** and Harris MB. Continuing improvement of outcome in childhood non-T, non-B acute lymphocytic leukemia (NNTNB-ALL); Pediatric Oncology Group (POG) experience in the 1980's. Blood 74(Suppl 1):292A, 1989.
17. Blume KG, Snyder DS, Chao NJ, Schmidt GM, **Amylon MD**, Konrad PN, Nademanee AP, O'Donnell MR, Parker PM, Stein AS and Forman SJ. Fractionated total body irradiation (FTBI) and high dose etoposide (VP-16) as preparation for allogeneic bone marrow transplantation (BMT) for patients with leukemia in first complete remission (CR). Blood 74(Suppl 1):756A, 1989.
18. Forman SJ, Schmidt GM, Chao NJ, Snyder DS, Nademanee SP, O'Donnell MR, Parker P, Stein A, Konrad P, Smith EP, Hill LR, **Amylon MD**, Brown BW and Blume KG. Cyclosporin A/prednisone/methotrexate (CSA/PSE/MTX) versus CSA/PSE for the prevention of acute graft versus host disease (GvHD): A prospective randomized study for patients in first complete remission. Blood 74(Suppl 1):916A, 1989.
19. Graham-Pole J, **Amylon M**, Effenbein G, Gallo J, Klemperer M, Jansen J, Lazarus H, Pick T, Rand K and Spruce W. Preventing systemic infections with IVIG - a randomized multicenter trial. Bone Marrow Transplantation 5(Suppl 2):132, 1990.
20. Chao NJ, Forman SJ, Schmidt GM, Snyder DS, **Amylon MD**, Konrad PN, Nademanee AP, O'Donnell MR and Parker PM. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during first complete remission. Exp Hematol 18(6):665, 1990.
21. Snyder D, Blume K, Chao N, Schmidt G, **Amylon M**, Konrad P, Nademanee A, O'Donnell M, Parker P, Stein A, Niland J, Degas A and Forman S. Fractionated total body irradiation (FTBI) and etoposide (VP-16): An effective preparative regimen for allogeneic bone marrow transplantation (BMT) for patients (pts) with leukemia in first complete remission (CR). Proc Am Soc Clin Oncol 10:740A, 1991.
22. Katz JA, **Amylon MD**, Ravindranath Y, Stout M, Shuster JJ, Jacaruso D and Murphy SB. Unexpected life-threatening toxicity from high dose cytosine arabinoside (HDA) in childhood T-cell acute lymphoblastic leukemia (T-ALL) and advanced stage lymphoblastic lymphoma (NHL): A Pediatric Oncology Group (POG) study. Blood 78(Suppl 1):143A, 1991.
23. Hunger SP, **Amylon MD**, Donlon TA and Cleary ML. Longitudinal monitoring of minimal residual disease (MRD) by PCR in a patient with Philadelphia chromosome, Blood (Suppl 1):1764A, 1991.
24. Bash RO, Crist WM, Link MP, Shuster JJ, **Amylon M**, Pullen J, Buchanan GR and Baer R. Clinical features and outcome in childhood T-cell acute lymphoblastic leukemia (T-ALL) with the *ta^d* rearrangement. Blood 78 (Suppl 1):325A, 1991.
25. Graham-Pole J, **Amylon M**, Effenbein G, Gallo J, Gross S, Jansen J, Klemperer M, Lazarus H, Pick T, Spruce W and Weiner R. Prophylactic intravenous immunoglobulin (IVIG) after allogeneic marrow transplant (BMT): preliminary analysis of a dose-randomizing study. J Cell Bio Suppl (part 16A):213, 1992.
26. Griffin TC and **Amylon MD**. Delayed clearance of blasts from peripheral blood following initiation of therapy is associated with an increased risk of relapse in children with T-cell ALL: A Pediatric Oncology Group (POG) study. Proc Am Soc Clin Oncol 11:932A, 1992.

27. **Amylon MD**, Carroll AJ, Link MP, Katz JA and Shuster JJ. Second malignancies in children treated with teniposide (VM-26) for T-cell lymphoid malignancy: a role for asparaginase? A Pediatric Oncology Group study. *Blood* 80(10, Suppl 1):206A, 1992.
28. Chao NJ, Schmidt GM, Niland JC, **Amylon MD**, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG and Forman SJ. A prospective randomized trial comparing cyclosporin-A and prednisone versus cyclosporin-A, methotrexate and prednisone for the prevention of acute graft-versus-host disease. *Blood* 80(10, Suppl 1):373A, 1992.
29. Katz J, Shuster J, Schneider N, **Amylon M**, Link M and Carroll A. The significance of ploidy in childhood T-cell acute lymphoblastic leukemia (T-ALL): a Pediatric Oncology Group study. *Proc Am Soc Clin Oncol* 12:316, 1993.
30. Stout M, Ravindranath Y, Kurtzberg J, Schwenn M, **Amylon M** and Katz J. Pharmacokinetics of high dose cytarabine in childhood T-cell acute lymphoblastic leukemia and advanced stage Burkitt's lymphoma: a Pediatric Oncology Group study. *Proc Am Soc Clin Oncol* 12:318, 1993.
31. Murphy SB, **Amylon M**, Link MP, Bowman WP, Brecher M, Pick T, Berard CW, Hutchinson R and Shuster JJ. For the Pediatric Oncology Group. Recent advances in therapy of high-grade T- and B- cell non-Hodgkin's lymphomas of childhood. *J Cell Bio Suppl* (part 17E):257, 1993.
32. Ravindranath Y, Stout M, Kurtzberg J, Schwenn M, **Amylon M** and Katz J. Pharmacokinetics of high dose cytarabine in childhood T-cell acute lymphoblastic leukemia and advanced stage Burkitt's lymphoma: a Pediatric Oncology Group study. Presented SIOP XXVth meeting October 7, 1993.
33. Katz JA, Schwenn M, **Amylon M**, Shuster JJ and Murphy SB. Evaluation of high dose L-asparaginase in treatment of childhood advanced stage lymphoblastic non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Presented SIOP XXVth meeting October 9, 1993.
34. **Amylon MD**, Co JP, Snyder DS, Forman SJ and Blume KG. Improved results of bone marrow transplantation for pediatric patients with early stage hematologic malignancies using a preparative regimen of fractionated total body irradiation with high dose Etoposide. *Blood* 10(1, Suppl 1):170A, 1993.
35. Yu AL, Heung RC, Uttenreuther M, Kim J, Link MP, Ochs J, Buchanan GR, **Amylon M** and Vietti T. Phase I trial of XomaZyme-H65 (H65-RTA) in children with T-cell acute lymphoblastic leukemia/lymphoma: A Pediatric Oncology Group (POG) study (POG 9074). *Proc Am Assoc Can Res* 35:211, 1994.
36. Priest J, Watterson J, Dehner L, Friend S, McIntyre J, Strong L, Hansen M, Byrd B, Feusner J, **Amylon M**, Bostrom B, Langston C and Pappo A. Childhood pleuropulmonary blastoma as a unique marker for familial childhood neoplasms. *Proc Am Soc Clin Oncol* 13:5, 1994.
37. Abella E, Katz J, Ravindranath Y, Schwenn M, Kurtzberg J, Shuster J, Steuber CP and **Amylon M**. Toxicity with high dose cytarabine in children: experience on Pediatric Oncology Group leukemia/lymphoma studies. *Proc Am Soc Clin Oncol* 13:19, 1994.
38. Long GD, **Amylon MD**, Chao NJ, Hoppe RT, Hoyle CF, Negrin RS and Blume KG. Fractionated total body irradiation, etoposide and cyclophosphamide (FTBI/VP-16/CY) followed by allogeneic bone marrow transplant (BMT) for poor risk or advanced stage hematological malignancies. *Proc Am Soc Clin Oncol* 13:315, 1994.

39. Mahmoud H, Schwartz C, Shuster J, Pui CH, Behm F, **Amylon M**, Raimondi S, Borowitz M, Link M, Pullen J, Camitta B, Hakami N, Crist W and Carroll A. The (11;19) translocation is associated with poor outcome in infants with acute lymphoblastic leukemia: a collaborative study of the POG and SJCRH. SIOP XXVIth meeting September 1994.
40. Katz JA, **Amylon MD**, Ravindranath Y and Shuster JJ. Evaluation of high dose Ara-C (HDA) in treatment of childhood T-cell acute lymphoblastic leukemia (T-ALL) and advanced stage lymphoblastic non-Hodgkin's lymphoma (LL): a Pediatric Oncology Group (POG) study. *Blood*, 84(10, Suppl 1):145A, 1994.
41. Blume KG, Long GD, Negrin RS, Chao NJ, Kusnierz-Glaz C and **Amylon MD**. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. *Bone Marrow Transplantation* 14(Suppl 4):S9-10, 1994.
42. Chao NJ, Schmidt GM, Niland JC, **Amylon MD**, Dagens AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, et al. Improved prophylaxis for acute graft-versus-host disease with cyclosporine, methotrexate, and prednisone compared to cyclosporine and prednisone: Results of a prospective randomized study. *J Cell Biochem Suppl* (18B):52, 1994.
43. Long GD, **Amylon MD**, Nademanee AP, Chao NJ, Hoppe RT, Negrin RS, Snyder DS, Forman SJ and Blume KG. Fractionated total body irradiation, etoposide and cyclophosphamide (FTBI/VP-16/CY) followed by allogeneic bone marrow transplantation (BMT) for high risk or advanced stage hematological malignancies. *Blood* 84(10, Suppl 1):205A, 1994.
44. Randle CJ, Frankel LR and **Amylon M**. Early identification of high risk pediatric patients with acute leukemia and pneumonia. *Chest* 106(Suppl 2):106S, 1994.
45. Katz JA, Shuster JJ, Ravindranath Y, Jacaruso D, Berard C and **Amylon MD**. Secondary acute myelogenous leukemia (AML) following intensive treatment for childhood T-cell acute lymphoblastic leukemia (T-ALL) and advanced stage lymphoblastic lymphoma (LL) treated with teniposide (VM-26): a Pediatric Oncology Group (POG) study. *Proc Am Soc Clin Oncol* 14:344 (1040A), 1995.
46. Kilroy KM, Frankel LR and **Amylon M**. Is fiberoptic bronchoscopy with bronchoalveolar lavage indicated in the asymptomatic child after bone marrow transplant? *J Invest Med* 43(Suppl 1):143A, 1995.
47. Yu AL, Diccianni MB, Batova A, Vu T, Pullen J, **Amylon M**, Pollock B and Yu J. High frequency alterations of the p16 and p15, but not p18, CDK inhibitors in T-cell acute lymphoblastic leukemia. *Blood* 86(10, Suppl 1): 268A, 1995.
48. Laver J, Katz J, Shuster J and **Amylon M**. Effects of rhG-CSF in an intensive treatment for T-cell leukemia and advanced stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group study. *Proc Am Soc Clin Oncol* 15:275 (736A), 1996.
49. Stockerl-Goldstein KE, Horning SJ, Chao NJ, Hu WW, Long GD, Negrin RS, Hoppe RT, **Amylon MD** and Blume KG. Evaluation of two preparative regimens for autologous bone marrow transplantation for non-Hodgkin's lymphoma: the Stanford experience. *Proc Am Soc Clin Oncol* 15:336, 1996.
50. Anderson R, Basran R, Blanchette N, Klein N, Muroff A, **Amylon M**, Brittenham GM, Mentzer W, Vichinsky EP and Olivieri NF. Long-term complications of bone marrow transplantation (BMT) in iron-loaded patients. *Blood* 88(10, Suppl 1):262a, 1996.

51. Lee YS, Kristovich KM, Ducore JM, Vichinsky E, Crouse VL, Glader BE and **Amylon MD**. Bone marrow transplant in thalassemia at Stanford: a role for radiation? *Blood* 88(10, Suppl 1):620a, 1996.
52. Geaghan S. **Amylon M**, and Link M. Pediatric acute lymphoblastic leukemia with eosinophilia and t(5;14). *Blood* 88(10, Suppl 1):155b, 1996.
53. Pajean TS, Lane D, Bennett CL, Land V, **Amylon M**, and Laver JH. Economic analysis of G-CSF use with intensive treatment for pediatric lymphoma and T-cell leukemia. *Blood* 90(10, Suppl 1):73a, 1997.
54. Yeager AM, **Amylon M**, Wagner J, Calderwood S, Anasetti C, Sender L, Jacobs C, Benyunes M. Allogeneic stem cell transplantation from HLA-haploidentical relatives as treatment for children with hematologic malignancy: a phase I/II study using mobilized peripheral blood progenitor cells that have undergone CD34 selection followed by CD2 depletion. *Blood* 90(10, Suppl 1):217a, 1997.
55. Ross M, Forman SJ, Wong RM, Schmidt GM, Niland JC, **Amylon MD**, Dagis AC, Long GD, Nademane AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Blume KG, and Chao NJ. A prospective randomized trial comparing cyclosporin A and prednisone versus cyclosporin A, methotrexate and prednisone for the prevention of acute graft-versus-host disease: effect on chronic graft-versus-host disease and long-term survival. *Blood* 90(10, Suppl 1):590a, 1997.
56. Griffin TC, Shuster JJ, Buchanan GR, Wharam M, Murphy SB, Camitta B and **Amylon M**. Slow reduction of peripheral blood blast count is an adverse prognostic factor in childhood T-cell acute lymphoblastic leukemia (T-ALL): A Pediatric Oncology Group study. *Proc Am Soc Clin Oncol* 17:527a, 1998.
57. Shah SJ, Taub JW, Radewan TL, Fu W, Moore D, Pollack BH, Zhang L, **Amylon M**, Behm FG, Pullen J, Ravindranath Y, and Matherly LH. Relationship of p15 and p16 gene deletions to elevated dihydrofolate reductase (DHFR) in childhood acute lymphoblastic leukemia (ALL). *Blood* 92(10, Suppl 1): 220a, 1998.
58. Snyder DS, Nademane AP, O'Donnell MR, Parker PM, Stein AS, Margolin K, Somlo G, Molina A, Spielberger R, Kashyap AA, Fung H, Vora N, Slovak ML, Dagis A, Negrin RS, **Amylon MD**, Blume KG, and Forman SJ. Allogeneic bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia in first complete remission: Long term follow-up. *Blood* 92(10, Suppl 1): 657a, 1998.
59. Savasan S, Buck S, Hamre M, Weinstein H, **Amylon M**, Becton D, Asselin B, and Ravindranath Y. Measurement of drug induced apoptosis for the assessment of in vitro drug sensitivity in childhood acute lymphoblastic leukemia: A new approach. *Blood* 92(10, Suppl 1): 195b, 1998.
60. Yeager AM, Calderwood S, **Amylon M**, Wagner JE, Anasetti C, Sing A, Jacobs C, and Horowitz MM. Transplantation of CD34 selected, CD2 depleted (CD34+/CD2-) peripheral blood progenitor cells (PBPCs) from HLA haploidentical relatives in children with high risk hematologic malignancies: Comparison with results of bone marrow transplantation (BMT) from HLA-matched unrelated donors (URDs). *Blood* 92(10, Suppl 1): 359b, 1998.

61. Lee Y, Marina NM, Dahl GV, and **Amylon MD**. Potentiation of hearing loss after bone marrow transplantation (BMT) for solid tumors using carboplatin-containing conditioning regimen. Proc Am Soc Clin Oncol 18:52a, 1999.
62. Laver JH, Barredo JC, **Amylon M**, Kurtzberg J, Camitta BM, Pullen J, Link M, Ravindranath Y, Murphy SB and Shuster J. Effects of cranial radiation in children with high risk T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group Report. Proc Am Soc Clin Oncol 18:565a, 1999.
63. Lee Y, Kristovich KM, Grumet FC, **Amylon MD**. Multi-lineage chimerism analysis using short or variable number of tandem repeat (STR/VNTR) polymerase chain reaction (PCR) in both bone marrow (BM) and peripheral blood (PB) from patients (pts) after allogeneic bone marrow transplantation (BMT). Blood 94(10, Suppl 1): 148a, 1999
64. Fung H, Jamieson C, Snyder D, O'Donnell M, Chao N, Stein A, Nademanee A, Molina A, Palmer JM, Negrin R, Hilger J, Slovak ML, Spielberger R, Parker P, Forman S, Kashyap A, Vora N, Krishnan A, Rodriguez R, Bhatia R, Niland JC, Senitzer D, Arber D, **Amylon M**, Arbayo C, Blume KG, Forman SJ. Allogeneic bone marrow transplantation (BMT) for AML in first remission (1CR) utilizing fractionated total body irradiation (FTBI) and VP-16; analysis of risk factors for relapse and disease-free survival. Blood 94(10, Suppl 1): 167a, 1999
65. Fung H, Jamieson C, Snyder D, O'Donnell M, Chao N, Stein A, Nademanee A, Molina A, Palmer JM, Negrin R, Hilger J, Slovak ML, Spielberger R, Parker P, Forman S, Kashyap A, Vora N, Krishnan A, Rodriguez R, Bhatia R, Niland JC, Senitzer D, Arber D, **Amylon M**, Arbayo C, Blume KG, Forman SJ. Allogeneic bone marrow transplantation (BMT) for high risk ALL in first remission (1CR). Blood 94(10, Suppl 1): 609a, 1999
66. Chao NJ, Snyder D, Jain M, Wong R, Niland J, Negrin RS, Long GD, Hu WW, Goldstein K, Johnston L, **Amylon M**, Tierney DK, O'Donnell M, Nademanee A, Parker P, Stein A, Molina A, Fung H, Kashyap A, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Blume KG. Equivalence of two effective GVHD prophylaxis regimens: results of a prospective blinded randomized trial. Blood 94(10, Suppl 1): 666a, 1999
67. Deeg HJ, **Amylon M**, Harris R, Collins R, Feig S, Beatty P, Territo M, Burdach S, Ramsey N, Khan S, Pamphilon D, Maziarz RT, Monroe D, Anasetti C, Seidel K. Marrow transplantation from unrelated donors for patients with aplastic anemia (AA) – optimization of a conditioning regimen. Blood 94(10, Suppl 1): 713a, 1999
68. Lee Y, Kristovich KM, Grumet FC, **Amylon MD**. Correction of relapsing hemophagocytic lymphohistiocytosis (HLH) after unrelated bone marrow transplantation (BMT) with donor lymphocyte infusion (DLI). Blood 94(10, Suppl 1): 378b, 1999
69. Stuart S. Winter, Jill J. Sweatman, Jonathan J. Shuster, **Michael D. Amylon**, Michael P. Link, and Richard S. Larson. Bone marrow stroma-supported recovery of T-lineage acute lymphoblastic leukemia (T-ALL) cells is prognostic of treatment outcome: a Pediatric Oncology Group study. Blood 96(11, Suppl 1): 111a, 2000
70. Asselin B, Shuster J, **Amylon M**, Halperin E, Hutchison R, Lipshultz S, Camitta B. Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) study. Proc Am Soc Clin Oncol 20:367a, 2001

71. Blanco JG, Edick MJ, Shuster JJ, Dervieux T, **Amylon MD**, Bash RO, Behm FG, Camitta BM, Pui CH, Raimondi SC, Winick NJ, Hancock ML, and Relling MV. Genetic polymorphisms in NQO1 and CYP3A4 in children with treatment-related acute myeloid malignancies. *Blood* 98(11): 323a, 2001
72. Iannone R, Casella JF, Fuchs EJ, Chen AR, Woolfrey A, **Amylon M**, Sullivan KM, Storb RF, and Walters MC. Failure of a minimally toxic non-myeloablative regimen to establish stable donor engraftment after transplantation for sickle cell anemia and β -thalassemia. *Blood* 100(11): 46a, 2002
73. Woolfrey A, Pulsipher MA, Walters MC, **Amylon M**, Thomson B, Sanders JE, and Storb R. A minimal toxicity nonmyeloablative transplant regimen for patients with non-malignant disorders. *Blood* 100(11): 623a, 2002
74. Jonasdottir S, Wong WB, Agarwal R, Wilson DM, **Amylon MD**, and Fechner PY. Bone marrow transplantation in children less than 3 years of age: long term effects on height and hormonal function. *Blood* 100(11): 850a, 2002
75. Woolfrey AE, Pulsipher M, Walters MC, **Amylon M**, Sanders JE, and Storb R. Minimal toxicity using fludarabine and low dose total body irradiation as conditioning for transplantation of HLA matched hematopoietic cells. Pediatric Academic Societies Annual Meeting, 2003.
76. Martiniuk, ALC, Shea-Perry, M, Silva, M, **Amylon, MD**, Briery, BG, Hale, S. Children's Oncology Camping Association International (Coca-I): Treating Clinic and Camp Liaison Survey for Quality Improvement of Oncology Camps. Abstract #243, SIOP, 2010.
77. Kharbanda, S, Agarwal, R, Miklos, DB, Porteus, M, **Amylon, M**, Willert, J, and Weinberg, KI. Hematopoietic Cell Transplantation (HCT) for Treatment of Genetic Lymphoheatoietic Diseases for Patients Lacking a Fully Matched Sibling Donor Using a Novel Conditioning Regimen. *Biology of Blood and Marrow Transplantation* 02/2013; 19(2):S250-S251. DOI: 10.1016/j.bbmt.2012.11.330.
78. Alderfer, M.A., Rico, K., Hildenbrand, A.K., Canter, K., McDonnell, G., Taggi Pinto, A., Stenman, K., Kazak, A.E., Lown, E.A., & **Amylon, M**. (March, 2020). Adapting evidence-based psychosocial care for pediatric oncology family camp: The Surviving Cancer CAMPetently (SCCamp) Program. In C. Amaro & M.A. Alderfer (Chairs), *Supporting Siblings of Youth with Chronic Medical Conditions: A Need for Innovation*. Podium presentation as part of a symposium at the Society of Pediatric Psychology Annual Conference, Dallas, TX.
79. Amaro, C. M., Devine, K. A., Senger, A., Canter, K. S., Fooks-Parker, S., **Amylon, M.**, Hudson, S., Manne, S. L., & Alderfer, M. A. (2023, August). Engaging community members in the development of a web-based single-session intervention for adolescent siblings of youth with cancer. In C. M. Amaro & M. A. Alderfer (Chairs), *Developing interventions with reach: Family-centered psychosocial care in pediatric oncology* [Symposium]. European Paediatric Psychology Conference, Stirling, Scotland.
80. Amaro, C. M., Horvath, L. A., Sirota, J., Senger, A., Patel, P., Silver, S., Canter, K. S., **Amylon, M.**, Fooks-Parker, S., Hudson, S. V., Alderfer, M. A., & Devine, K. A. (2023, October). *Community members' preferences for a single-session intervention for adolescent siblings of children with cancer* [Poster Presentation]. Rutgers Cancer Institute - Ludwig Princeton Branch at Princeton University Annual Cancer Research Symposium, Princeton, NJ.

81. Amaro, C. M., Horvath, L. A., Sirota, J., Collins, M., Silver, S., Patel, P., Senger, A., Canter, K. S., Fooks-Parker, S., **Amylon, M.**, Hudson, S. V., Alderfer, M. A., & Devine, K. S. (2024, March 6-8). *Engaging community members in developing a digital single-session intervention for adolescent siblings of children with cancer* [Poster accepted for presentation]. American Psychosocial Oncology Society Annual Conference, Albuquerque, NM, United States.
82. Amaro, C. M., Alderfer, M.A., Fooks-Parker, S., **Amylon, M.**, Canter, K.S., Hudson, S. V., Schleider, J.L., & Devine, K. A. (2024, December). *Exploring preferences for a digital single-session intervention for adolescent siblings of youth with cancer*. [Oral Presentation]. 6th Global Adolescent and Young Adult Cancer Congress, Melbourne, Australia.
83. Alderfer, M.A., Canter, K., Hildenbrand, A.K., Rico, K., Taggi Pinto, A., Kazak, A.E., & **Amylon, M.** (2025, August). Meeting Families Where They Choose to Be: Preliminary Feasibility and Acceptability of Surviving Cancer CAMPetently (SCCamp) at Pediatric Oncology Family Camp. Abstract presentation. 18th International Congress of Behavioral Medicine, Vienna, Austria.
84. Alderfer, M.A., Canter, K., Hildenbrand, A.K., Rico, K., Taggi Pinto, A., Kazak, A.E., & **Amylon, M.** (2025, May). Meeting Families Where They Choose to Be: Preliminary Feasibility and Acceptability of Surviving Cancer CAMPetently (SCCamp) at Pediatric Oncology Family Camp. Poster presentation. Nemours Research Week, Wilmington, DE.
85. Amaro, C.M., Silver, S., Patel, P., Paek, H., McDonnell, K. A., Ramji, A. V., Huang, M., Canter, K. S., **Amylon, M.**, Fooks-Parker, S., Hudson, S. V., Schleider, J. L., Alderfer, M. A., & Devine, K. A. (2026, March). Centering community perspectives in the development of a digital single-session intervention for adolescent siblings of youth with cancer. In D. R. Jutagir & C. M. Amaro (Chairs), *Development of Single-Session and Brief Interventions to Expand Access to Psychosocial Oncology* [Symposium]. American Psychosocial Oncology Society Conference, New Orleans, Louisiana, USA.